Treating traumatic bleeding in a combat setting.

Bleeding is clearly a major cause of morbidity and death after trauma. When bleeding is attributable to transection of major vessels, surgical repair is appropriate. Posttraumatic microvascular bleeding attributable to coagulopathy secondary to metabolic derangements, hypothermia, and depletion or dysfunction of cellular and protein components requires a different approach. Although transfusion of blood products may be necessary to replace the blood loss, it does not always correct the problem of microvascular bleeding. The type of injury, mode of care, and treatment objectives differ significantly for combat-wounded soldiers versus civilian trauma patients. Although hemorrhage is responsible for 50% of combat deaths, published information about coagulation monitoring among combat patients is very limited. These articles summarize the appropriate monitoring of hemostasis among combat trauma patients, review the unique nature of combat casualties and the medical system used to treat them, and discuss information available from civilian studies. Because the development of coagulopathy is relatively infrequent in the young, otherwise healthy, military population, the routine screening measures currently used are adequate to guide initial blood product administration. However, as new intravenous hemostatic agents are used for these patients, better laboratory measures will be required. Although hemorrhage is the leading cause of death for combat casualties, catastrophic hemorrhage is rarely a prehospital combat medical management problem because, when it occurs, it tends to cause death before medical care can be provided. In civilian environments, most seriously injured victims can be reached and transported by emergency medical services personnel within minutes; in combat, it often takes hours simply to transport casualties off the battlefield. In combat situations, even if the transport distances are small, the hazardous nature of the forward combat areas frequently prevents medical personnel from quickly reaching the wounded. Furthermore, whereas civilian blunt trauma victims may have a "golden hour," casualties with penetrating battlefield trauma often have only a "platinum 5 minutes." Because of the challenges of treating hemorrhage during combat, it is important for military medical personnel to understand their options for treating hemorrhage quickly and efficiently. These articles discuss the causes of posttraumatic microvascular bleeding and the potential treatment options for controlling catastrophic hemorrhage in combat areas.

[1]  K. Sainio,et al.  Pneumatic tourniquet paralysis. Case report. , 1983, The Journal of bone and joint surgery. British volume.

[2]  J. Holcomb,et al.  Efficacy of a dry fibrin sealant dressing for hemorrhage control after ballistic injury. , 1998, Archives of surgery.

[3]  R. Balderston,et al.  Pathophysiologic effects distal to a tourniquet in the dog. , 1979, Journal of Trauma.

[4]  G. Waylonis,et al.  Effect of tourniquet time on postoperative quadriceps function. , 1979, Clinical orthopaedics and related research.

[5]  J. Holcomb,et al.  Does the absorbable fibrin adhesive bandage facilitate partial nephrectomy? , 2000, The Journal of urology.

[6]  S. Cohn,et al.  Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study. , 2002, The Journal of trauma.

[7]  U Martinowitz,et al.  Recombinant activated factor VII for adjunctive hemorrhage control in trauma. , 2001, The Journal of trauma.

[8]  G. Majno,et al.  The Healing Hand: Man and Wound in the Ancient World , 1975 .

[9]  L. Klenerman,et al.  The effect of pneumatic tourniquets on the ultrastructure of skeletal muscle. , 1979, The Journal of bone and joint surgery. British volume.

[10]  S. Schwaitzberg,et al.  Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage. , 2000, The Journal of trauma.

[11]  D. Essex,et al.  Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. , 2002, The Journal of trauma.

[12]  J. Holcomb,et al.  Effect of dry fibrin sealant dressings versus gauze packing on blood loss in grade V liver injuries in resuscitated swine. , 1998, The Journal of trauma.

[13]  J. Anema,et al.  Treatment of grade 4 renal stab wounds with absorbable fibrin adhesive bandage in a porcine model. , 2001, The Journal of urology.

[14]  D. Tweardy,et al.  The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries. , 2003, Journal of the American College of Surgeons.

[15]  J. Fridén,et al.  Muscle injury induced beneath and distal to a pneumatic tourniquet: a quantitative animal study of effects of tourniquet pressure and duration. , 1991, The Journal of hand surgery.

[16]  R. Bergman,et al.  Tourniquet ischemia: ultrastructural and histochemical observations of ischemic human muscle and of monkey muscle and nerve. , 1977, The Journal of hand surgery.

[17]  J. Holcomb,et al.  Fibrin sealant foam sprayed directly on liver injuries decreases blood loss in resuscitated rats. , 2000, The Journal of trauma.

[18]  Richard A. Harris,et al.  Effect of a chitosan-based hemostatic dressing on blood loss and survival in a model of severe venous hemorrhage and hepatic injury in swine. , 2003, The Journal of trauma.

[19]  Peter Rhee,et al.  Comparative analysis of hemostatic agents in a swine model of lethal groin injury. , 2003, The Journal of trauma.

[20]  R. Weiskopf Intraoperative use of recombinant activated coagulation factor vII. , 2002, Anesthesiology.

[21]  G. Lin,et al.  Tourniquets for hemorrhage control on the battlefield: a 4-year accumulated experience. , 2003, The Journal of trauma.

[22]  R. Lim,et al.  Efficacy of a fibrin hemostatic bandage in controlling hemorrhage from experimental arterial injuries. , 1995, Archives of surgery.

[23]  M. D. Jacobson,et al.  Muscle Functional Deficits After Tourniquet Ischemia , 1994, The American journal of sports medicine.

[24]  J Hagmann,et al.  Tactical combat casualty care in special operations. , 1996, Military medicine.

[25]  A. Nitz,et al.  Postmeniscectomy tourniquet palsy and functional sequelae , 1982, The American journal of sports medicine.

[26]  A A Sapega,et al.  Optimizing tourniquet application and release times in extremity surgery. A biochemical and ultrastructural study. , 1985, The Journal of bone and joint surgery. American volume.

[27]  S. P. Kent,et al.  THE USE OF BASIC POLYSACCHARIDES IN HISTOCHEMISTRY AND CYTOCHEMISTRY: IV. PRECIPITATION AND AGGLUTINATION OF BIOLOGICAL MATERIALS BY ASPERGILLUS POLYSACCHARIDE AND DEACETYLATED CHITIN , 1962 .

[28]  D. Altchek,et al.  Does tourniquet use during anterior cruciate ligament surgery interfere with postsurgical recovery of function? A review of the literature. , 1991, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[29]  J. Holcomb,et al.  The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. , 2002, The Journal of trauma.

[30]  R. Coupland,et al.  The tourniquet controversy. , 2003, The Journal of trauma.

[31]  F. Butler Tactical combat casualty care: combining good medicine with good tactics. , 2003, The Journal of trauma.

[32]  R. Pedowitz,et al.  Tourniquet-induced neuromuscular injury. A recent review of rabbit and clinical experiments. , 1991, Acta orthopaedica Scandinavica. Supplementum.